NEW YORK (TheStreet) -- Furiex Pharmaceuticals (FURX) surged 28.57% to $103.05 at the close of trading on Monday after Forest Laboratories (FRX) announced it would acquire the company for $1.5 billion.
This deal comes more than two months after news that Actavis, based in Ireland, would buy Forest for approximately $25 billion in a deal that should close in mid-2014. Forest said Monday that Actavis agreed to and supports the Furiex acquisition, according to USA Today.
Forest said it would pay approximately $1.1 billion in cash, or $95 per share, for Furiex. and would pay an additional amount of up to approximately $360 million depending on the development of eluxadoline. The drug treats symptoms of diarrhea-predominant irritable bowel syndrome, which affects nearly 28 million people in the U.S. and Europe.
Several law firms subsequently announced investigations into the deal.Must Read: Warren Buffett's 10 Favorite Growth Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV